title: Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
abstract: OBJECTIVE
  Ivacaftor was approved in 2012 to treat patients with cystic fibrosis (CF) with specific CFTR gene mutations. The objective of this analysis was to analyze the impact of ivacaftor on health resource utilization through analysis of claims data.
  
  
  METHODS
  Patients diagnosed with CF aged ≥6 years prescribed ivacaftor between January 1, 2012 and July 31, 2014 with ≥12 months of continuous insurance coverage prior to and following the prescription were identified. All-cause and CF-specific healthcare resource utilization during the pre- and post-prescription periods and ivacaftor adherence levels were studied.
  
  
  RESULTS
  The 79 identified patients had a mean age of 20.8 years, and 54% were female. The proportion of patients with inpatient admissions (all-cause and CF-related) was significantly higher in the pre index compared to post index period (p ≤ 0.05). Mean ivacaftor medication possession ratio was 0.8 (SD = 0.3), and 73% of patients had a medication possession ratio >0.80.
  
  
  CONCLUSIONS
  Only a small number of patients met the inclusion criteria. Additionally, claims data may contain errors or inconsistencies and cannot be used to determine if medications were taken as prescribed.
  
  
  CONCLUSIONS
  Ivacaftor therapy was associated with significant reductions in hospitalizations along with high rates of adherence to treatment over 12 months.
authors.affiliation: a Vertex Pharmaceuticals Incorporated , Boston , MA , USA ;
authors.forename: Ellison D
authors.initials: ED
authors.lastname: Suthoff
authors.affiliation: b Truven Health Analytics , Cambridge , MA , USA ;
authors.forename: Mac
authors.initials: M
authors.lastname: Bonafede
authors.affiliation: b Truven Health Analytics , Cambridge , MA , USA ;
authors.forename: Brendan
authors.initials: B
authors.lastname: Limone
authors.affiliation: a Vertex Pharmaceuticals Incorporated , Boston , MA , USA ;
authors.forename: Lasair
authors.initials: L
authors.lastname: O'Callaghan
authors.affiliation: c Division of Respiratory Diseases , Boston Children's Hospital , Boston , MA , USA ;
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Sawicki
authors.affiliation: d Department of Pediatrics , University of Colorado Medical School , Aurora , CO , USA.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Wagener
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000627:Aminophenols / Q000191:economics* / Q000627:therapeutic use; D002648:Child; D065101:Chloride Channel Agonists / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000191:economics*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D005260:Female; D005102:Health Expenditures / Q000706:statistics & numerical data; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data*; D006801:Humans; D007348:Insurance, Health / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009154:Mutation; D015363:Quinolones / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies; D012737:Sex Factors; D055815:Young Adult
chemical_list: D000627:Aminophenols; C505032:CFTR protein, human; D065101:Chloride Channel Agonists; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor
keywords: Adherence; Healthcare resource utilization; Ivacaftor: Cystic fibrosis; Medication possession ratio; Pulmonary exacerbation